from Reuters Video: Business https://ift.tt/2P5Or7X
Moderna’s hoped-for $8 bln IPO valuation is a rich antidote to the funk hitting tech stocks. Rob Cyran explains that although the biotech firm’s technology is promising, it has no drugs near commercial readiness. That’s all the more reason to grab the money while it can.
from Reuters Video: Business https://ift.tt/2P5Or7X
from Reuters Video: Business https://ift.tt/2P5Or7X
Hello, my name is Muhammad Salman.I am 17 Years Old BLogger and Graphics Designer .
No comments:
Post a Comment